U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from MedGen

Items: 1 to 20 of 104

1.
Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
Anita J. Brogan, Sandra E. Talbird, James R. Thompson, Jeffrey D. Miller, Jaime Rubin, Baris Deniz
PLoS One. 2014; 9(3): e90295. Published online 2014 Mar 6. doi: 10.1371/journal.pone.0090295
PMCID:
PMC3946047
AbstractArticlePDF–278K
2.
Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with Hepatitis C Virus Genotype 1
Norio Akuta, Fumitaka Suzuki, Taito Fukushima, Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Tasuku Hara, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
J Clin Microbiol. 2013 Sep; 51(9): 2862–2868. doi: 10.1128/JCM.01129-13
PMCID:
PMC3754631
AbstractArticlePDF–264K
3.
New Preclinical Antimalarial Drugs Potently Inhibit Hepatitis C Virus Genotype 1b RNA Replication
Youki Ueda, Midori Takeda, Kyoko Mori, Hiromichi Dansako, Takaji Wakita, Hye-Sook Kim, Akira Sato, Yusuke Wataya, Masanori Ikeda, Nobuyuki Kato
PLoS One. 2013; 8(8): e72519. Published online 2013 Aug 30. doi: 10.1371/journal.pone.0072519
Correction in:
PLoS One. 2013; 8(9): 10.1371/annotation/6e1f1f8f-c421-4def-aaf1-4ce7f4915d87.
PMCID:
PMC3758303
AbstractArticlePDF–2.5M
4.
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman, Steven L. Flamm, Nezam H. Afdhal, David R. Nelson, Mark S. Sulkowski, Gregory T. Everson, Michael W. Fried, Michael Adler, Hendrik W. Reesink, Marie Martin, Abdul J. Sankoh, Nathalie Adda, Robert S. Kauffman, Shelley George, Christopher I. Wright, Fred Poordad
N Engl J Med. Author manuscript; available in PMC 2013 Oct 28.
Published in final edited form as: N Engl J Med. 2011 Sep 15; 365(11): 10.1056/NEJMoa1014463. doi: 10.1056/NEJMoa1014463
Correction in:
volume 365 on page 1551
PMCID:
PMC3809077
AbstractArticlePDF–209K
5.
Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?
Alessandro Grasso, Federica Malfatti, Roberto Testa
World J Gastroenterol. 2013 Nov 7; 19(41): 6947–6956. Published online 2013 Nov 7. doi: 10.3748/wjg.v19.i41.6947
PMCID:
PMC3819530
AbstractArticlePDF–1.1M
6.
Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
Kazi Abdus Salam, Nobuyoshi Akimitsu
Biomed Res Int. 2013; 2013: 467869. Published online 2013 Oct 27. doi: 10.1155/2013/467869
PMCID:
PMC3825274
AbstractArticlePDF–864K
7.
Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results
Christoph R. Werner, Daniel P. Egetemeyr, Ulrich M. Lauer, Silvio Nadalin, Alfred Königsrainer, Nisar P. Malek, Christoph P. Berg
PLoS One. 2013; 8(11): e80528. Published online 2013 Nov 12. doi: 10.1371/journal.pone.0080528
PMCID:
PMC3827217
AbstractArticlePDF–357K
8.
Adapted J6/JFH1-Based Hepatitis C Virus Recombinants with Genotype-Specific NS4A Show Similar Efficacies against Lead Protease Inhibitors, Alpha Interferon, and a Putative NS4A Inhibitor
Judith M. Gottwein, Sanne B. Jensen, Stéphanie B. N. Serre, Lubna Ghanem, Troels K. H. Scheel, Tanja B. Jensen, Henrik Krarup, Nathalie Uzcategui, Lotte S. Mikkelsen, Jens Bukh
Antimicrob Agents Chemother. 2013 Dec; 57(12): 6034–6049. doi: 10.1128/AAC.01176-13
PMCID:
PMC3837860
AbstractArticlePDF–4.6M
9.
In Vitro Phenotypic Characterization of Hepatitis C Virus NS3 Protease Variants Observed in Clinical Studies of Telaprevir
Min Jiang, Nagraj Mani, Chao Lin, Andrzej Ardzinski, Michelle Nelson, Dugan Reagan, Doug Bartels, Yi Zhou, Olivier Nicolas, B. Govinda Rao, Ute Müh, Brian Hanzelka, Ann Tigges, Rene Rijnbrand, Tara L. Kieffer
Antimicrob Agents Chemother. 2013 Dec; 57(12): 6236–6245. doi: 10.1128/AAC.01578-13
PMCID:
PMC3837892
AbstractArticlePDF–618K
10.
Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and –experienced patients
Armin D Goralczyk, Silke Cameron, Ahmad Amanzada
BMC Gastroenterol. 2013; 13: 148. Published online 2013 Oct 14. doi: 10.1186/1471-230X-13-148
PMCID:
PMC3852825
AbstractArticlePDF–746K
11.
Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review
Shuang Wu, Tatsuo Kanda, Shingo Nakamoto, Fumio Imazeki, Osamu Yokosuka
World J Gastroenterol. 2013 Dec 21; 19(47): 8940–8948. Published online 2013 Dec 21. doi: 10.3748/wjg.v19.i47.8940
PMCID:
PMC3870547
AbstractArticlePDF–1.1M
12.
Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells
Jin-Ching Lee, Chin-Kai Tseng, Kung-Chia Young, Hung-Yu Sun, Shainn-Wei Wang, Wei-Chun Chen, Chun-Kuang Lin, Yu-Hsuan Wu
Br J Pharmacol. 2014 Jan; 171(1): 237–252. Published online 2013 Dec 10. doi: 10.1111/bph.12440
PMCID:
PMC3874710
AbstractArticlePDF–1.9M
13.
Utility of Detection of Telaprevir-Resistant Variants for Prediction of Efficacy of Treatment of Hepatitis C Virus Genotype 1 Infection
Norio Akuta, Fumitaka Suzuki, Taito Fukushima, Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Tasuku Hara, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
J Clin Microbiol. 2014 Jan; 52(1): 193–200. doi: 10.1128/JCM.02371-13
PMCID:
PMC3911448
AbstractArticlePDF–1.0M
14.
Restoration of the Activated Rig-I Pathway in Hepatitis C Virus (HCV) Replicon Cells by HCV Protease, Polymerase, and NS5A Inhibitors In Vitro at Clinically Relevant Concentrations
Gururaj Kalkeri, Chao Lin, Jenna Gopilan, Kevin Sloan, Rene Rijnbrand, Ann D. Kwong
Antimicrob Agents Chemother. 2013 Sep; 57(9): 4417–4426. doi: 10.1128/AAC.00399-13
PMCID:
PMC3754339
AbstractArticlePDF–1.7M
15.
Hepatitis C Treatment & Management
D Andronescu, S Diaconu, N Tiuca, RM Purcarea, CI Andronescu
J Med Life. 2014 Mar 15; 7(1): 31–36. Published online 2014 Mar 25.
PMCID:
PMC3956092
AbstractArticlePDF–530K
16.
Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
Nicola Coppola, Mariantonietta Pisaturo, Caterina Sagnelli, Evangelista Sagnelli, Italo F. Angelillo
PLoS One. 2014; 9(4): e94542. Published online 2014 Apr 11. doi: 10.1371/journal.pone.0094542
PMCID:
PMC3984165
AbstractArticlePDF–722K
17.
PCR-Based In Vitro Synthesis of Hepatitis C Virus NS3 Protease for Rapid Phenotypic Resistance Testing of Protease Inhibitors
Jinjuan Qiao, Junping Yu, Hang Yang, Hongping Wei
J Clin Microbiol. 2014 Apr; 52(4): 1139–1145. doi: 10.1128/JCM.03257-13
PMCID:
PMC3993517
AbstractArticlePDF–813K
18.
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals
Liesl M. Hagan, Mark S. Sulkowski, Raymond F. Schinazi
Hepatology. Author manuscript; available in PMC 2015 Jul 1.
Published in final edited form as: Hepatology. 2014 Jul; 60(1): 37–45. Published online 2014 May 14. doi: 10.1002/hep.27151
PMCID:
PMC4077973
AbstractArticlePDF–577K
19.
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
M Colombo, I Fernández, D Abdurakhmanov, P A Ferreira, S I Strasser, P Urbanek, C Moreno, A Streinu-Cercel, A Verheyen, W Iraqi, R DeMasi, A Hill, J M Läuffer, I Lonjon-Domanec, H Wedemeyer
Gut. 2014 Jul; 63(7): 1150–1158. Published online 2013 Nov 7. doi: 10.1136/gutjnl-2013-305667
PMCID:
PMC4078754
AbstractArticlePDF–754K
20.
Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection
Malte H Wehmeyer, Friederike Eißing, Sabine Jordan, Claudia Röder, Annette Hennigs, Olaf Degen, Anja Hüfner, Sandra Hertling, Stefan Schmiedel, Martina Sterneck, Jan van Lunzen, Ansgar W Lohse, Julian Schulze zur Wiesch, Stefan Lüth
BMC Gastroenterol. 2014; 14: 87. Published online 2014 May 5. doi: 10.1186/1471-230X-14-87
PMCID:
PMC4102246
AbstractArticlePDF–759K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center